宣郁化毒汤联合索拉非尼治疗原发性肝癌术后复发患者的临床观察  

Clinical Study of Xuanyu Huadu Decoction Combined with Sorafenib in the Treat⁃ment of Patients with Postoperative Recurrece of Primary Liver Cancer

作　　者：姚姗姗 燕腾飞 王久利 徐海军 张国利 YAO Shan-shan;YAN Teng-fei;WANG Yong-li;XU Hai-jun;ZHANG Guo-li(Department of Oncology,Bozhou Hospital of Traditional Chinese Medicine,Bozhou Anhui 236800;Bozhou College of Anhui Province,Bozhou Anhui 236840)

机构地区：[1]安徽省亳州市中医院肿瘤科,安徽亳州236800 [2]安徽省亳州学院,安徽亳州236840

出　　处：《世界中西医结合杂志》2023年第10期2081-2085,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：2018年安徽省自然科学基金项目(1808085QC78)。

摘　　要：目的探讨宣郁化毒汤联合索拉非尼治疗原发性肝癌(Primary liver cancer,PLC)术后复发患者的临床疗效。方法选取2019年5月—2020年5月期间安徽省亳州市中医院肿瘤科收治的经动脉化疗栓塞术后复发患者100例作为研究对象,按随机数字表法分为对照组和观察组,每组各50例。对照组进行索拉非尼治疗,观察组在对照组基础上加用宣郁化毒汤治疗,持续治疗4个疗程后予以疗效评估,并对两组患者进行12个月的随访。观察比较两组患者临床疗效、不良反应及随访情况,治疗前后肿瘤标志物和炎症因子[甲胎蛋白(Alpha-feto⁃protein,AFP)、恶性肿瘤特异性生长因子(Tumor-specific growth factor,TSGF)、血管内皮生长因子(vascular endo⁃thelial growth factor,VEGF)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)]、中医证候积分、肝功能指标[天冬氨酸氨基转移酶(Aspartate aminotransferase,AST)、丙氨酸氨基转移酶(Alanine aminotransferase,ALT)、白蛋白(Albumin,ALB)、总胆红素(Total bilirubin,TBil)]。结果治疗后观察组临床总有效率74.00%(37/50)明显高于对照组46.00%(23/50),差异有统计学意义(P<0.05)。治疗后两组患者血清TSGF、AFP、VEGF、TNF-α及IL-6水平均较治疗前降低,差异有统计学意义(P<0.05);且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,差异有统计学意义(P<0.05);且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清AST、ALT、TB、ALB水平均较治疗前降低,差异有统计学意义(P<0.05);且观察组低于对照组,差异有统计学意义(P<0.05)。随访期间,观察组存活率80.00%明显高于对照组52.00%,差异有统计学意义(P<0.05)。两组患者消化道反应、高血压及手足综合征的发生率比较,差异无统计学意义(P>0.05)。结论宣郁化毒汤联合索拉非尼是治疗经动脉化疗�Objective To explore the clinical efficacy of Xuanyu Huadu Decoction combined with sorafenib in the treatment of patients with recurrent primary liver cancer after surgery.Methods A total of 100 patients admitted to Oncol⁃ogy Department of Bozhou Hospital of Traditional Chinese Medicine in Anhui Province from May 2019 to May 2020 were selected as the research objects,and were divided into control group and observation group according to random number ta⁃ble method,with 50 cases in each group.The patients in control group were treated with sorafenib,and on this basis,the pa⁃tients in observation group were treated with Xuanyu Huadu Decoction.After 4 courses of treatment,the efficacy was evalu⁃ated,and the patients in the two groups were followed up for 12 months.Clinical efficacy,adverse reactions and follow-up were observed and compared between the two groups.The levels of tumor markers and inflammatory factors(Alpha-feto⁃protein(AFP),tumor-specific growth factor(TSGF),vascular endothelial growth factor(VEGF),tumor necrosis factor-α(TNF-α),Interleukin-6(IL-6))were detected before and after treatment in the two groups.Before and after treat⁃ment,TCM syndrome scores and liver function indexes(aspartate aminotransferase(AST),alanine aminotransferase(ALT),albumin(ALB)and total bilirubin(TBil))were compared between the two groups.and the 12-month survival was counted,and the safety of medication was evaluated in the two groups.Results The total clinical effective rate of the ob⁃servation group after treatment was 74.00%(37/50)and was significantly higher than that of the control group of 46.00%(23/50),and the difference was statistically significant(P<0.05).After treatment,the serum levels of TSGF,AFP,VEGF,TNF-αand IL-6 were lower than those before treatment(P<0.05);and the observation group was lower than the control group(P<0.05).After treatment,the score of TCM syndrome in both groups was decreased compared with that before treatment,and the difference was statistically significant(P<0.05).Moreover

关 键 词：宣郁化毒汤 索拉非尼 经动脉化疗栓塞 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]